ID   MET_HUMAN               Reviewed;        1390 AA.
AC   P08581; A1L467; B5A932; E7EQ94; O60366; Q12875; Q9UDX7; Q9UPL8;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 4.
DT   10-MAY-2017, entry version 227.
DE   RecName: Full=Hepatocyte growth factor receptor;
DE            Short=HGF receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=HGF/SF receptor;
DE   AltName: Full=Proto-oncogene c-Met;
DE   AltName: Full=Scatter factor receptor;
DE            Short=SF receptor;
DE   AltName: Full=Tyrosine-protein kinase Met;
DE   Flags: Precursor;
GN   Name=MET;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=2819873; DOI=10.1073/pnas.84.18.6379;
RA   Park M., Dean M., Kaul K., Braun M.J., Gonda M.A., Vande Woude G.;
RT   "Sequence of MET protooncogene cDNA has features characteristic of the
RT   tyrosine kinase family of growth-factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6379-6383(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Giordano S.;
RL   Submitted (NOV-1990) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1010-1390.
RX   PubMed=3325883;
RA   Chan A.M.-L., King H.W.S., Tempest P.R., Deakin E.A., Cooper C.S.,
RA   Brookes P.;
RT   "Primary structure of the met protein tyrosine kinase domain.";
RL   Oncogene 1:229-233(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1206-1264.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1267-1390.
RX   PubMed=4069211; DOI=10.1038/318385a0;
RA   Dean M., Park M., le Beau M.M., Robins T.S., Diaz M.O., Rowley J.D.,
RA   Blair D.G., Vande Woude G.F.;
RT   "The human met oncogene is related to the tyrosine kinase oncogenes.";
RL   Nature 318:385-388(1985).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=1917129; DOI=10.1002/ijc.2910490302;
RA   Prat M., Narsimhan R.P., Crepaldi T., Nicotra M.R., Natali P.G.,
RA   Comoglio P.M.;
RT   "The receptor encoded by the human c-MET oncogene is expressed in
RT   hepatocytes, epithelial cells and solid tumors.";
RL   Int. J. Cancer 49:323-328(1991).
RN   [12]
RP   INTERACTION WITH PIK3R1.
RX   PubMed=1718989;
RA   Graziani A., Gramaglia D., Cantley L.C., Comoglio P.M.;
RT   "The tyrosine-phosphorylated hepatocyte growth factor/scatter factor
RT   receptor associates with phosphatidylinositol 3-kinase.";
RL   J. Biol. Chem. 266:22087-22090(1991).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=1719465;
RA   Di Renzo M.F., Narsimhan R.P., Olivero M., Bretti S., Giordano S.,
RA   Medico E., Gaglia P., Zara P., Comoglio P.M.;
RT   "Expression of the Met/HGF receptor in normal and neoplastic human
RT   tissues.";
RL   Oncogene 6:1997-2003(1991).
RN   [14]
RP   FUNCTION.
RX   PubMed=1846706; DOI=10.1126/science.1846706;
RA   Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M.-L., Kmiecik T.E.,
RA   Vande Woude G.F., Aaronson S.A.;
RT   "Identification of the hepatocyte growth factor receptor as the c-met
RT   proto-oncogene product.";
RL   Science 251:802-804(1991).
RN   [15]
RP   PHOSPHORYLATION AT TYR-1235, AND ATP-BINDING SITE LYS-1110.
RX   PubMed=1655790;
RA   Ferracini R., Longati P., Naldini L., Vigna E., Comoglio P.M.;
RT   "Identification of the major autophosphorylation site of the
RT   Met/hepatocyte growth factor receptor tyrosine kinase.";
RL   J. Biol. Chem. 266:19558-19564(1991).
RN   [16]
RP   PHOSPHORYLATION AT TYR-1349 AND TYR-1356, AND INTERACTION WITH SRC;
RP   PLCG1 AND GRB2.
RX   PubMed=7513258; DOI=10.1016/0092-8674(94)90318-2;
RA   Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P.,
RA   Giordano S., Graziani A., Panayotou G., Comoglio P.M.;
RT   "A multifunctional docking site mediates signaling and transformation
RT   by the hepatocyte growth factor/scatter factor receptor family.";
RL   Cell 77:261-271(1994).
RN   [17]
RP   FUNCTION IN WOUND HEALING.
RX   PubMed=8182137; DOI=10.1172/JCI117200;
RA   Nusrat A., Parkos C.A., Bacarra A.E., Godowski P.J., Delp-Archer C.,
RA   Rosen E.M., Madara J.L.;
RT   "Hepatocyte growth factor/scatter factor effects on epithelia.
RT   Regulation of intercellular junctions in transformed and
RT   nontransformed cell lines, basolateral polarization of c-met receptor
RT   in transformed and natural intestinal epithelia, and induction of
RT   rapid wound repair in a transformed model epithelium.";
RL   J. Clin. Invest. 93:2056-2065(1994).
RN   [18]
RP   INTERACTION WITH STAT3.
RX   PubMed=9440692; DOI=10.1038/34657;
RA   Boccaccio C., Ando M., Tamagnone L., Bardelli A., Michieli P.,
RA   Battistini C., Comoglio P.M.;
RT   "Induction of epithelial tubules by growth factor HGF depends on the
RT   STAT pathway.";
RL   Nature 391:285-288(1998).
RN   [19]
RP   INTERACTION WITH GRB10.
RX   PubMed=10454568; DOI=10.1128/MCB.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [20]
RP   INTERACTION WITH RANBP9.
RX   PubMed=12147692; DOI=10.1074/jbc.M205111200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "Activation of Ras/Erk pathway by a novel MET-interacting protein
RT   RanBPM.";
RL   J. Biol. Chem. 277:36216-36222(2002).
RN   [21]
RP   UBIQUITINATION, MUTAGENESIS OF TYR-1234; TYR-1235; TYR-1313; TYR-1349;
RP   TYR-1356 AND TYR-1365, AND CHARACTERIZATION OF VARIANT SER-1003.
RX   PubMed=12244174; DOI=10.4049/jimmunol.169.7.3793;
RA   Taher T.E., Tjin E.P., Beuling E.A., Borst J., Spaargaren M.,
RA   Pals S.T.;
RT   "c-Cbl is involved in Met signaling in B cells and mediates hepatocyte
RT   growth factor-induced receptor ubiquitination.";
RL   J. Immunol. 169:3793-3800(2002).
RN   [22]
RP   INTERACTION WITH PLXNB1.
RX   PubMed=12198496; DOI=10.1038/ncb843;
RA   Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G.,
RA   Barberis D., Tamagnone L., Comoglio P.M.;
RT   "The semaphorin 4D receptor controls invasive growth by coupling with
RT   Met.";
RL   Nat. Cell Biol. 4:720-724(2002).
RN   [23]
RP   PHOSPHORYLATION AT TYR-1230; TYR-1234; TYR-1235; TYR-1349 AND
RP   TYR-1365, AND DEPHOSPHORYLATION AT TYR-1349 AND TYR-1365 BY PTPRJ.
RX   PubMed=12475979; DOI=10.1074/jbc.M210656200;
RA   Palka H.L., Park M., Tonks N.K.;
RT   "Hepatocyte growth factor receptor tyrosine kinase met is a substrate
RT   of the receptor protein-tyrosine phosphatase DEP-1.";
RL   J. Biol. Chem. 278:5728-5735(2003).
RN   [24]
RP   INTERACTION WITH RANBP9 AND RANBP10.
RX   PubMed=14684163; DOI=10.1016/j.bbrc.2003.11.124;
RA   Wang D., Li Z., Schoen S.R., Messing E.M., Wu G.;
RT   "A novel MET-interacting protein shares high sequence similarity with
RT   RanBPM, but fails to stimulate MET-induced Ras/Erk signaling.";
RL   Biochem. Biophys. Res. Commun. 313:320-326(2004).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH MUC20.
RX   PubMed=15314156; DOI=10.1128/MCB.24.17.7456-7468.2004;
RA   Higuchi T., Orita T., Katsuya K., Yamasaki Y., Akiyama K., Li H.,
RA   Yamamoto T., Saito Y., Nakamura M.;
RT   "MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras
RT   pathway by binding to a multifunctional docking site of met.";
RL   Mol. Cell. Biol. 24:7456-7468(2004).
RN   [26]
RP   PHOSPHORYLATION AT TYR-1356, AND INTERACTION WITH INPPL1.
RX   PubMed=15735664; DOI=10.1038/sj.onc.1208558;
RA   Koch A., Mancini A., El Bounkari O., Tamura T.;
RT   "The SH2-domain-containing inositol 5-phosphatase (SHIP)-2 binds to c-
RT   Met directly via tyrosine residue 1356 and involves hepatocyte growth
RT   factor (HGF)-induced lamellipodium formation, cell scattering and cell
RT   spreading.";
RL   Oncogene 24:3436-3447(2005).
RN   [27]
RP   REVIEW ON FUNCTION IN ANGIOGENESIS.
RX   PubMed=16862193; DOI=10.1038/nrc1912;
RA   Boccaccio C., Comoglio P.M.;
RT   "Invasive growth: a MET-driven genetic programme for cancer and stem
RT   cells.";
RL   Nat. Rev. Cancer 6:637-645(2006).
RN   [28]
RP   PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1 AND PTPN2, INTERACTION
RP   WITH PTPN1 AND PTPN2, AND MUTAGENESIS OF TYR-1234 AND TYR-1235.
RX   PubMed=18819921; DOI=10.1074/jbc.M805916200;
RA   Sangwan V., Paliouras G.N., Abella J.V., Dube N., Monast A.,
RA   Tremblay M.L., Park M.;
RT   "Regulation of the Met receptor-tyrosine kinase by the protein-
RT   tyrosine phosphatase 1B and T-cell phosphatase.";
RL   J. Biol. Chem. 283:34374-34383(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-977 AND TYR-1003, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-990; SER-997 AND
RP   SER-1000, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-106.
RC   TISSUE=Hepatoma;
RX   PubMed=19196183; DOI=10.1021/pr800826u;
RA   Cao J., Shen C., Wang H., Shen H., Chen Y., Nie A., Yan G., Lu H.,
RA   Liu Y., Yang P.;
RT   "Identification of N-glycosylation sites on secreted proteins of human
RT   hepatocellular carcinoma cells with a complementary proteomics
RT   approach.";
RL   J. Proteome Res. 8:662-672(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1003 AND THR-1289, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [33]
RP   REVIEW ON FUNCTION.
RX   PubMed=20655987; DOI=10.1016/j.bbcan.2010.07.006;
RA   Mahtouk K., Tjin E.P., Spaargaren M., Pals S.T.;
RT   "The HGF/MET pathway as target for the treatment of multiple myeloma
RT   and B-cell lymphomas.";
RL   Biochim. Biophys. Acta 1806:208-219(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   INTERACTION WITH GAB1.
RX   PubMed=21784853; DOI=10.1074/jbc.M111.239384;
RA   Chaudhuri A., Xie M.H., Yang B., Mahapatra K., Liu J., Marsters S.,
RA   Bodepudi S., Ashkenazi A.;
RT   "Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal
RT   transduction by the related receptor tyrosine kinases RON and MET.";
RL   J. Biol. Chem. 286:32762-32774(2011).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-990, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-966, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [38]
RP   INVOLVEMENT IN OSFD, VARIANT OSFD 964-LEU--ASP-1010 DEL, TISSUE
RP   SPECIFICITY, AND UBIQUITINATION.
RX   PubMed=26637977; DOI=10.1016/j.ajhg.2015.11.001;
RA   Gray M.J., Kannu P., Sharma S., Neyt C., Zhang D., Paria N.,
RA   Daniel P.B., Whetstone H., Sprenger H.G., Hammerschmidt P., Weng A.,
RA   Dupuis L., Jobling R., Mendoza-Londono R., Dray M., Su P.,
RA   Wilson M.J., Kapur R.P., McCarthy E.F., Alman B.A., Howard A.,
RA   Somers G.R., Marshall C.R., Manners S., Flanagan A.M., Rathjen K.E.,
RA   Karol L.A., Crawford H., Markie D.M., Rios J.J., Wise C.A.,
RA   Robertson S.P.;
RT   "Mutations preventing regulated exon skipping in MET cause
RT   osteofibrous dysplasia.";
RL   Am. J. Hum. Genet. 97:837-847(2015).
RN   [39]
RP   INVOLVEMENT IN DFNB97, AND VARIANT DFNB97 VAL-841.
RX   PubMed=25941349; DOI=10.1136/jmedgenet-2015-103023;
RA   Mujtaba G., Schultz J.M., Imtiaz A., Morell R.J., Friedman T.B.,
RA   Naz S.;
RT   "A mutation of MET, encoding hepatocyte growth factor receptor, is
RT   associated with human DFNB97 hearing loss.";
RL   J. Med. Genet. 52:548-552(2015).
RN   [40]
RP   INTERACTION WITH HSP90AA1 AND HSP90AB1.
RX   PubMed=26517842; DOI=10.1371/journal.pone.0141786;
RA   Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K.,
RA   Rivas C., Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T.,
RA   Beebe K., Trepel J.B., Neckers L.;
RT   "Client proteins and small molecule inhibitors display distinct
RT   binding preferences for constitutive and stress-induced HSP90 isoforms
RT   and their conformationally restricted mutants.";
RL   PLoS ONE 10:E0141786-E0141786(2015).
RN   [41]
RP   INTERACTION WITH LECT2.
RX   PubMed=27334921; DOI=10.1074/jbc.M116.720375;
RA   Zheng H., Miyakawa T., Sawano Y., Asano A., Okumura A., Yamagoe S.,
RA   Tanokura M.;
RT   "Crystal structure of human leukocyte cell-derived chemotaxin 2
RT   (LECT2) reveals a mechanistic basis of functional evolution in a
RT   mammalian protein with an M23 metalloendopeptidase fold.";
RL   J. Biol. Chem. 291:17133-17142(2016).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1356-1359 IN COMPLEX WITH
RP   GRB2.
RX   PubMed=11063574; DOI=10.1021/bi0012336;
RA   Schiering N., Casale E., Caccia P., Giordano P., Battistini C.;
RT   "Dimer formation through domain swapping in the crystal structure of
RT   the Grb2-SH2-Ac-pYVNV complex.";
RL   Biochemistry 39:13376-13382(2000).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1049-1360 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=14559966; DOI=10.1073/pnas.1734128100;
RA   Schiering N., Knapp S., Marconi M., Flocco M.M., Cui J., Perego R.,
RA   Rusconi L., Cristiani C.;
RT   "Crystal structure of the tyrosine kinase domain of the hepatocyte
RT   growth factor receptor c-Met and its complex with the microbial
RT   alkaloid K-252a.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:12654-12659(2003).
RN   [44]
RP   STRUCTURE BY NMR OF 519-562, AND DISULFIDE BONDS.
RX   PubMed=15358240; DOI=10.1016/j.bbrc.2004.06.132;
RA   Kozlov G., Perreault A., Schrag J.D., Park M., Cygler M., Gehring K.,
RA   Ekiel I.;
RT   "Insights into function of PSI domains from structure of the Met
RT   receptor PSI domain.";
RL   Biochem. Biophys. Res. Commun. 321:234-240(2004).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (3.22 ANGSTROMS) OF 25-567 IN COMPLEX WITH HGF,
RP   AND DISULFIDE BONDS.
RX   PubMed=15167892; DOI=10.1038/sj.emboj.7600243;
RA   Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C.;
RT   "Crystal structure of the HGF beta-chain in complex with the Sema
RT   domain of the Met receptor.";
RL   EMBO J. 23:2325-2335(2004).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 25-740 IN COMPLEX WITH
RP   L.MONOCYTOGENES INLB, AND DISULFIDE BONDS.
RX   PubMed=17662939; DOI=10.1016/j.cell.2007.05.037;
RA   Niemann H.H., Jager V., Butler P.J., van den Heuvel J., Schmidt S.,
RA   Ferraris D., Gherardi E., Heinz D.W.;
RT   "Structure of the human receptor tyrosine kinase met in complex with
RT   the Listeria invasion protein InlB.";
RL   Cell 130:235-246(2007).
RN   [47]
RP   VARIANTS RCCP THR-1131; LEU-1188; VAL-1195; ILE-1220; HIS-1228;
RP   ASN-1228; CYS-1230; HIS-1230 AND THR-1250, AND VARIANT VAL-320.
RX   PubMed=9140397; DOI=10.1038/ng0597-68;
RA   Schmidt L., Duh F.-M., Chen F., Kishida T., Glenn G., Choyke P.,
RA   Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R.,
RA   Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C.,
RA   Zamarron A., Bernues M., Richard S., Lips C.J.M., Walther M.M.,
RA   Tsui L.-C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L.,
RA   Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S.,
RA   Lerman M.I., Linehan W.M., Zbar B.;
RT   "Germline and somatic mutations in the tyrosine kinase domain of the
RT   MET proto-oncogene in papillary renal carcinomas.";
RL   Nat. Genet. 16:68-73(1997).
RN   [48]
RP   VARIANT RCCP ARG-1094, AND CHARACTERIZATION OF VARIANT RCCP ARG-1094.
RX   PubMed=9563489;
RA   Schmidt L., Junker K., Weirich G., Glenn G., Choyke P., Lubensky I.,
RA   Zhuang Z., Jeffers M., Vande Woude G., Neumann H., Walther M.,
RA   Linehan W.M., Zbar B.;
RT   "Two North American families with hereditary papillary renal carcinoma
RT   and identical novel mutations in the MET proto-oncogene.";
RL   Cancer Res. 58:1719-1722(1998).
RN   [49]
RP   VARIANTS RCCP ILE-1092; ARG-1094; ASP-1106; THR-1131; LEU-1188;
RP   ASP-1230; CYS-1230 AND THR-1250.
RX   PubMed=10433944; DOI=10.1016/S0002-9440(10)65147-4;
RA   Lubensky I.A., Schmidt L., Zhuang Z., Weirich G., Pack S.,
RA   Zambrano N., Walther M.M., Choyke P., Linehan W.M., Zbar B.;
RT   "Hereditary and sporadic papillary renal carcinomas with c-met
RT   mutations share a distinct morphological phenotype.";
RL   Am. J. Pathol. 155:517-526(1999).
RN   [50]
RP   VARIANTS HCC ILE-1173; ARG-1244 AND ILE-1250.
RX   PubMed=9927037;
RA   Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J.,
RA   Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S.,
RA   Zhuang Z., Schmidt L., Zbar B., Lee J.Y.;
RT   "Somatic mutations in the kinase domain of the Met/hepatocyte growth
RT   factor receptor gene in childhood hepatocellular carcinomas.";
RL   Cancer Res. 59:307-310(1999).
RN   [51]
RP   VARIANT RCCP ILE-1092, AND CHARACTERIZATION OF VARIANT RCCP ILE-1092.
RX   PubMed=10417759;
RX   DOI=10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6;
RA   Olivero M., Valente G., Bardelli A., Longati P., Ferrero N.,
RA   Cracco C., Terrone C., Rocca-Rossetti S., Comoglio P.M.,
RA   Di Renzo M.F.;
RT   "Novel mutation in the ATP-binding site of the MET oncogene tyrosine
RT   kinase in a HPRCC family.";
RL   Int. J. Cancer 82:640-643(1999).
RN   [52]
RP   VARIANTS RCCP ILE-1092; LEU-1094; TYR-1094; ASP-1106 AND ASP-1230, AND
RP   CHARACTERIZATION OF VARIANTS RCCP ILE-1092; LEU-1094; TYR-1094;
RP   ASP-1106 AND ASP-1230.
RX   PubMed=10327054; DOI=10.1038/sj.onc.1202547;
RA   Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G.,
RA   Miller M., Lubensky I., Neumann H.P.H., Brauch H., Decker J.,
RA   Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U.,
RA   Gerrard B., Dean M., Linehan W.M., Zbar B.;
RT   "Novel mutations of the MET proto-oncogene in papillary renal
RT   carcinomas.";
RL   Oncogene 18:2343-2350(1999).
RN   [53]
RP   VARIANT GASTRIC CANCER SER-991, VARIANT ILE-992, CHARACTERIZATION OF
RP   VARIANT GASTRIC CANCER SER-991, AND CHARACTERIZATION OF VARIANT
RP   ILE-992.
RX   PubMed=11042681; DOI=10.1038/sj.onc.1203874;
RA   Lee J.-H., Han S.-U., Cho H., Jennings B., Gerrard B., Dean M.,
RA   Schmidt L., Zbar B., Vande Woude G.F.V.;
RT   "A novel germ line juxtamembrane Met mutation in human gastric
RT   cancer.";
RL   Oncogene 19:4947-4953(2000).
RN   [54]
RP   VARIANT GASTRIC CANCER LEU-773.
RX   PubMed=12920089; DOI=10.1136/jmg.40.8.e97;
RA   Kim I.-J., Park J.-H., Kang H.C., Shin Y., Lim S.-B., Ku J.-L.,
RA   Yang H.-K., Lee K.U., Park J.-G.;
RT   "A novel germline mutation in the MET extracellular domain in a Korean
RT   patient with the diffuse type of familial gastric cancer.";
RL   J. Med. Genet. 40:E97-E97(2003).
RN   [55]
RP   INTERACTION WITH SPSB1; SPSB2; SPSB3 AND SPSB4.
RX   PubMed=15713673; DOI=10.1074/jbc.M413897200;
RA   Wang D., Li Z., Messing E.M., Wu G.;
RT   "The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with
RT   MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum
RT   response element pathway.";
RL   J. Biol. Chem. 280:16393-16401(2005).
RN   [56]
RP   POSSIBLE INVOLVEMENT IN SUSCEPTIBILITY TO AUTS9, AND VARIANTS CYS-970
RP   AND ILE-992.
RX   PubMed=17053076; DOI=10.1073/pnas.0605296103;
RA   Campbell D.B., Sutcliffe J.S., Ebert P.J., Militerni R., Bravaccio C.,
RA   Trillo S., Elia M., Schneider C., Melmed R., Sacco R., Persico A.M.,
RA   Levitt P.;
RT   "A genetic variant that disrupts MET transcription is associated with
RT   autism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:16834-16839(2006).
RN   [57]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-143; LEU-156; ASP-168; SER-375;
RP   CYS-970 AND ILE-992.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [58]
RP   VARIANTS TYR-150; ASP-168; TYR-385; ILE-992 AND ILE-1294,
RP   CHARACTERIZATION OF VARIANTS TYR-150; ASP-168; TYR-385; ILE-992 AND
RP   ILE-1294, AND POSSIBLE INVOLVEMENT IN CUP.
RX   PubMed=20949619; DOI=10.1002/humu.21374;
RA   Stella G.M., Benvenuti S., Gramaglia D., Scarpa A., Tomezzoli A.,
RA   Cassoni P., Senetta R., Venesio T., Pozzi E., Bardelli A.,
RA   Comoglio P.M.;
RT   "MET mutations in cancers of unknown primary origin (CUPs).";
RL   Hum. Mutat. 32:44-50(2011).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from
CC       the extracellular matrix into the cytoplasm by binding to
CC       hepatocyte growth factor/HGF ligand. Regulates many physiological
CC       processes including proliferation, scattering, morphogenesis and
CC       survival. Ligand binding at the cell surface induces
CC       autophosphorylation of MET on its intracellular domain that
CC       provides docking sites for downstream signaling molecules.
CC       Following activation by ligand, interacts with the PI3-kinase
CC       subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1.
CC       Recruitment of these downstream effectors by MET leads to the
CC       activation of several signaling cascades including the RAS-ERK,
CC       PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is
CC       associated with the morphogenetic effects while PI3K/AKT
CC       coordinates prosurvival effects. During embryonic development, MET
CC       signaling plays a role in gastrulation, development and migration
CC       of muscles and neuronal precursors, angiogenesis and kidney
CC       formation. In adults, participates in wound healing as well as
CC       organ regeneration and tissue remodeling. Promotes also
CC       differentiation and proliferation of hematopoietic cells. May
CC       regulate cortical bone osteogenesis (By similarity).
CC       {ECO:0000250|UniProtKB:P16056}.
CC   -!- FUNCTION: Acts as a receptor for Listeria internalin inlB,
CC       mediating entry of the pathogen into cells.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: In its inactive state, the C-terminal tail
CC       interacts with the catalytic domain and inhibits the kinase
CC       activity. Upon ligand binding, the C-terminal tail is displaced
CC       and becomes phosphorylated, thus increasing the kinase activity.
CC   -!- SUBUNIT: Heterodimer made of an alpha chain (50 kDa) and a beta
CC       chain (145 kDa) which are disulfide linked. Binds PLXNB1.
CC       Interacts when phosphorylated with downstream effectors including
CC       STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1,
CC       SPSB2 and SPSB4 (By similarity). Interacts with INPP5D/SHIP1. When
CC       phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts
CC       with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4.
CC       SPSB1 binding occurs in the presence and in the absence of HGF,
CC       however HGF treatment has a positive effect on this interaction.
CC       Interacts with MUC20; prevents interaction with GRB2 and
CC       suppresses hepatocyte growth factor-induced cell proliferation.
CC       Interacts with GRB10. Interacts with PTPN1 and PTPN2. Interacts
CC       with LECT2; this interaction may have an antagonistic effect on
CC       receptor activation (PubMed:27334921). Interacts with HSP90AA1 and
CC       HSP90AB1; the interaction suppresses MET kinase activity
CC       (PubMed:26517842). {ECO:0000250|UniProtKB:P16056,
CC       ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:11063574,
CC       ECO:0000269|PubMed:12147692, ECO:0000269|PubMed:12198496,
CC       ECO:0000269|PubMed:14559966, ECO:0000269|PubMed:14684163,
CC       ECO:0000269|PubMed:15167892, ECO:0000269|PubMed:15314156,
CC       ECO:0000269|PubMed:15713673, ECO:0000269|PubMed:15735664,
CC       ECO:0000269|PubMed:1718989, ECO:0000269|PubMed:17662939,
CC       ECO:0000269|PubMed:18819921, ECO:0000269|PubMed:21784853,
CC       ECO:0000269|PubMed:26517842, ECO:0000269|PubMed:27334921,
CC       ECO:0000269|PubMed:7513258, ECO:0000269|PubMed:9440692}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=15; IntAct=EBI-1039152, EBI-518228;
CC       Q96EY1-2:DNAJA3; NbExp=2; IntAct=EBI-1039152, EBI-3952284;
CC       P00533:EGFR; NbExp=7; IntAct=EBI-1039152, EBI-297353;
CC       P09769:FGR; NbExp=2; IntAct=EBI-1039152, EBI-1383732;
CC       P14210:HGF; NbExp=4; IntAct=EBI-1039152, EBI-1039104;
CC       P14210-6:HGF; NbExp=2; IntAct=EBI-1039152, EBI-6280319;
CC       P25147:inlB (xeno); NbExp=4; IntAct=EBI-1039152, EBI-1379295;
CC       O15357:INPPL1; NbExp=2; IntAct=EBI-1039152, EBI-1384248;
CC       P35968:KDR; NbExp=3; IntAct=EBI-1039152, EBI-1005487;
CC       P35918:Kdr (xeno); NbExp=3; IntAct=EBI-1039152, EBI-1555005;
CC       P06239:LCK; NbExp=3; IntAct=EBI-1039152, EBI-1348;
CC       P07948:LYN; NbExp=2; IntAct=EBI-1039152, EBI-79452;
CC       P15941:MUC1; NbExp=2; IntAct=EBI-1039152, EBI-2804728;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1039152, EBI-389883;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-1039152, EBI-713635;
CC       P27986:PIK3R1; NbExp=6; IntAct=EBI-1039152, EBI-79464;
CC       O00459:PIK3R2; NbExp=11; IntAct=EBI-1039152, EBI-346930;
CC       Q92569:PIK3R3; NbExp=11; IntAct=EBI-1039152, EBI-79893;
CC       P19174:PLCG1; NbExp=10; IntAct=EBI-1039152, EBI-79387;
CC       O43157:PLXNB1; NbExp=7; IntAct=EBI-1039152, EBI-1111488;
CC       O15031:PLXNB2; NbExp=2; IntAct=EBI-1039152, EBI-722004;
CC       Q9ULL4:PLXNB3; NbExp=2; IntAct=EBI-1039152, EBI-311073;
CC       Q00944:PTK2 (xeno); NbExp=5; IntAct=EBI-1039152, EBI-2896409;
CC       P18031:PTPN1; NbExp=3; IntAct=EBI-1039152, EBI-968788;
CC       Q06124:PTPN11; NbExp=13; IntAct=EBI-1039152, EBI-297779;
CC       P23467:PTPRB; NbExp=2; IntAct=EBI-1039152, EBI-1265766;
CC       Q12913:PTPRJ; NbExp=5; IntAct=EBI-1039152, EBI-2264500;
CC       P20936:RASA1; NbExp=15; IntAct=EBI-1039152, EBI-1026476;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-1039152, EBI-7879749;
CC       O60880:SH2D1A; NbExp=3; IntAct=EBI-1039152, EBI-6983382;
CC       O14796:SH2D1B; NbExp=6; IntAct=EBI-1039152, EBI-3923013;
CC       Q9NP31:SH2D2A; NbExp=7; IntAct=EBI-1039152, EBI-490630;
CC       Q8N5H7:SH2D3C; NbExp=4; IntAct=EBI-1039152, EBI-745980;
CC       Q15464:SHB; NbExp=4; IntAct=EBI-1039152, EBI-4402156;
CC       P29353:SHC1; NbExp=5; IntAct=EBI-1039152, EBI-78835;
CC       P98077:SHC2; NbExp=2; IntAct=EBI-1039152, EBI-7256023;
CC       Q6S5L8:SHC4; NbExp=3; IntAct=EBI-1039152, EBI-9453524;
CC       Q96IW2:SHD; NbExp=2; IntAct=EBI-1039152, EBI-4402781;
CC       Q9H6Q3:SLA2; NbExp=4; IntAct=EBI-1039152, EBI-1222854;
CC       O75159:SOCS5; NbExp=2; IntAct=EBI-1039152, EBI-970130;
CC       O14544:SOCS6; NbExp=4; IntAct=EBI-1039152, EBI-3929549;
CC       P12931:SRC; NbExp=4; IntAct=EBI-1039152, EBI-621482;
CC       Q9ULZ2:STAP1; NbExp=3; IntAct=EBI-1039152, EBI-6083058;
CC       P43405:SYK; NbExp=3; IntAct=EBI-1039152, EBI-78302;
CC       P42680:TEC; NbExp=2; IntAct=EBI-1039152, EBI-1383480;
CC       Q9HBL0:TNS1; NbExp=2; IntAct=EBI-1039152, EBI-3389814;
CC       Q63HR2:TNS2; NbExp=2; IntAct=EBI-1039152, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=3; IntAct=EBI-1039152, EBI-1220488;
CC       Q9UKW4:VAV3; NbExp=2; IntAct=EBI-1039152, EBI-297568;
CC       P07947:YES1; NbExp=3; IntAct=EBI-1039152, EBI-515331;
CC       P43403:ZAP70; NbExp=2; IntAct=EBI-1039152, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional soluble isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P08581-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08581-2; Sequence=VSP_005005;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=Soluble MET variant 4;
CC         IsoId=P08581-3; Sequence=VSP_042447, VSP_042448;
CC   -!- TISSUE SPECIFICITY: Expressed in normal hepatocytes as well as in
CC       epithelial cells lining the stomach, the small and the large
CC       intestine. Found also in basal keratinocytes of esophagus and
CC       skin. High levels are found in liver, gastrointestinal tract,
CC       thyroid and kidney. Also present in the brain. Expressed in
CC       metaphyseal bone (at protein level) (PubMed:26637977).
CC       {ECO:0000269|PubMed:1719465, ECO:0000269|PubMed:1917129,
CC       ECO:0000269|PubMed:26637977}.
CC   -!- DOMAIN: The kinase domain is involved in SPSB1 binding.
CC   -!- DOMAIN: The beta-propeller Sema domain mediates binding to HGF.
CC   -!- PTM: Autophosphorylated in response to ligand binding on Tyr-1234
CC       and Tyr-1235 in the kinase domain leading to further
CC       phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal
CC       multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-
CC       1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2.
CC       {ECO:0000269|PubMed:12475979, ECO:0000269|PubMed:15735664,
CC       ECO:0000269|PubMed:1655790, ECO:0000269|PubMed:18819921,
CC       ECO:0000269|PubMed:7513258}.
CC   -!- PTM: Ubiquitinated. Ubiquitination by CBL regulates MET
CC       endocytosis, resulting in decreasing plasma membrane receptor
CC       abundance, and in endosomal degradation and/or recycling of
CC       internalized receptors. {ECO:0000269|PubMed:12244174,
CC       ECO:0000305|PubMed:26637977}.
CC   -!- DISEASE: Note=Activation of MET after rearrangement with the TPR
CC       gene produces an oncogenic protein.
CC   -!- DISEASE: Note=Defects in MET may be associated with gastric
CC       cancer.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk
CC       factors for HCC are chronic hepatitis B virus (HBV) infection,
CC       chronic hepatitis C virus (HCV) infection, prolonged dietary
CC       aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to
CC       other causes. {ECO:0000269|PubMed:9927037}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Renal cell carcinoma papillary (RCCP) [MIM:605074]: A
CC       subtype of renal cell carcinoma tending to show a tubulo-papillary
CC       architecture formed by numerous, irregular, finger-like
CC       projections of connective tissue. Renal cell carcinoma is a
CC       heterogeneous group of sporadic or hereditary carcinoma derived
CC       from cells of the proximal renal tubular epithelium.
CC       {ECO:0000269|PubMed:10327054, ECO:0000269|PubMed:10417759,
CC       ECO:0000269|PubMed:10433944, ECO:0000269|PubMed:9140397,
CC       ECO:0000269|PubMed:9563489}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A common allele in the promoter region of the MET
CC       shows genetic association with susceptibility to autism in some
CC       families. Functional assays indicate a decrease in MET promoter
CC       activity and altered binding of specific transcription factor
CC       complexes.
CC   -!- DISEASE: Note=MET activating mutations may be involved in the
CC       development of a highly malignant, metastatic syndrome known as
CC       cancer of unknown primary origin (CUP) or primary occult
CC       malignancy. Systemic neoplastic spread is generally a late event
CC       in cancer progression. However, in some instances, distant
CC       dissemination arises at a very early stage, so that metastases
CC       reach clinical relevance before primary lesions. Sometimes, the
CC       primary lesions cannot be identified in spite of the progresses in
CC       the diagnosis of malignancies.
CC   -!- DISEASE: Deafness, autosomal recessive, 97 (DFNB97) [MIM:616705]:
CC       A form of non-syndromic sensorineural hearing loss with prelingual
CC       onset. Sensorineural deafness results from damage to the neural
CC       receptors of the inner ear, the nerve pathways to the brain, or
CC       the area of the brain that receives sound information.
CC       {ECO:0000269|PubMed:25941349}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Osteofibrous dysplasia (OSFD) [MIM:607278]: A congenital
CC       disorder of osteogenesis characterized by non-neoplastic,
CC       radiolucent lesions that affect the cortical bone immediately
CC       under the periosteum. It usually manifests as a painless swelling
CC       or anterior bowing of the long bones, most commonly the tibia and
CC       fibula. {ECO:0000269|PubMed:26637977}. Note=Disease susceptibility
CC       is associated with variations affecting the gene represented in
CC       this entry. Disease-associated variants identified in 4 families
CC       cause the deletion of exon 14. This results in the exclusion of an
CC       ubiquitination target site within the cytoplasmic domain, hence in
CC       protein stabilization. The persistent presence of MET at the cell
CC       surface in conditions of ligand-dependent activation retards
CC       osteoblastic differentiation. {ECO:0000269|PubMed:26637977}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/METID131.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=C-MET entry;
CC       URL="https://en.wikipedia.org/wiki/C-MET";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02958; AAA59591.1; -; mRNA.
DR   EMBL; X54559; CAB56793.1; -; mRNA.
DR   EMBL; EU826570; ACF47606.1; -; mRNA.
DR   EMBL; AC002080; AAB54047.1; -; Genomic_DNA.
DR   EMBL; AC002543; AAC60383.1; -; Genomic_DNA.
DR   EMBL; AC004416; AAF66137.2; -; Genomic_DNA.
DR   EMBL; CH236947; EAL24359.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83509.1; -; Genomic_DNA.
DR   EMBL; BC130420; AAI30421.1; -; mRNA.
DR   EMBL; U08818; AAB60323.1; ALT_SEQ; mRNA.
DR   EMBL; M35074; AAA59590.1; -; mRNA.
DR   CCDS; CCDS43636.1; -. [P08581-1]
DR   CCDS; CCDS47689.1; -. [P08581-2]
DR   PIR; A40175; TVHUME.
DR   RefSeq; NP_000236.2; NM_000245.3. [P08581-1]
DR   RefSeq; NP_001120972.1; NM_001127500.2. [P08581-2]
DR   UniGene; Hs.132966; -.
DR   PDB; 1FYR; X-ray; 2.40 A; I/J/K/L=1356-1359.
DR   PDB; 1R0P; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1R1W; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 1SHY; X-ray; 3.22 A; B=25-567.
DR   PDB; 1SSL; NMR; -; A=519-562.
DR   PDB; 1UX3; Model; -; A=25-656.
DR   PDB; 2G15; X-ray; 2.15 A; A=1038-1346.
DR   PDB; 2RFN; X-ray; 2.50 A; A/B=1048-1351.
DR   PDB; 2RFS; X-ray; 2.20 A; A=1048-1351.
DR   PDB; 2UZX; X-ray; 2.80 A; B/D=25-740.
DR   PDB; 2UZY; X-ray; 4.00 A; B/D=25-740.
DR   PDB; 2WD1; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 2WGJ; X-ray; 2.00 A; A=1051-1348.
DR   PDB; 2WKM; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3A4P; X-ray; 2.54 A; A=1049-1360.
DR   PDB; 3BUX; X-ray; 1.35 A; A/C=997-1009.
DR   PDB; 3C1X; X-ray; 2.17 A; A=1049-1360.
DR   PDB; 3CCN; X-ray; 1.90 A; A=1048-1350.
DR   PDB; 3CD8; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 3CE3; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3CTH; X-ray; 2.30 A; A=1049-1360.
DR   PDB; 3CTJ; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3DKC; X-ray; 1.52 A; A=1049-1360.
DR   PDB; 3DKF; X-ray; 1.80 A; A=1049-1360.
DR   PDB; 3DKG; X-ray; 1.91 A; A=1049-1360.
DR   PDB; 3EFJ; X-ray; 2.60 A; A/B=1048-1351.
DR   PDB; 3EFK; X-ray; 2.20 A; A/B=1048-1351.
DR   PDB; 3F66; X-ray; 1.40 A; A/B=1052-1349.
DR   PDB; 3F82; X-ray; 2.50 A; A=1049-1360.
DR   PDB; 3I5N; X-ray; 2.00 A; A=1048-1350.
DR   PDB; 3L8V; X-ray; 2.40 A; A=1049-1360.
DR   PDB; 3LQ8; X-ray; 2.02 A; A=1051-1348.
DR   PDB; 3Q6U; X-ray; 1.60 A; A=1048-1348.
DR   PDB; 3Q6W; X-ray; 1.75 A; A=1048-1348.
DR   PDB; 3QTI; X-ray; 2.00 A; A/B=1050-1360.
DR   PDB; 3R7O; X-ray; 2.30 A; A=1048-1348.
DR   PDB; 3RHK; X-ray; 1.94 A; A/B=1038-1346.
DR   PDB; 3U6H; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 3U6I; X-ray; 2.10 A; A=1048-1351.
DR   PDB; 3VW8; X-ray; 2.10 A; A=1024-1352.
DR   PDB; 3ZBX; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3ZC5; X-ray; 2.20 A; A=1051-1348.
DR   PDB; 3ZCL; X-ray; 1.40 A; A=1051-1348.
DR   PDB; 3ZXZ; X-ray; 1.80 A; A=1051-1348.
DR   PDB; 3ZZE; X-ray; 1.87 A; A=1051-1348.
DR   PDB; 4AOI; X-ray; 1.90 A; A=1051-1348.
DR   PDB; 4AP7; X-ray; 1.80 A; A=1051-1348.
DR   PDB; 4DEG; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 4DEH; X-ray; 2.00 A; A=1048-1351.
DR   PDB; 4DEI; X-ray; 2.05 A; A=1048-1351.
DR   PDB; 4EEV; X-ray; 1.80 A; A=1038-1346.
DR   PDB; 4GG5; X-ray; 2.42 A; A=1038-1346.
DR   PDB; 4GG7; X-ray; 2.27 A; A=1038-1346.
DR   PDB; 4IWD; X-ray; 1.99 A; A=1048-1348.
DR   PDB; 4K3J; X-ray; 2.80 A; B=39-564.
DR   PDB; 4KNB; X-ray; 2.40 A; A/B/C/D=1060-1346.
DR   PDB; 4MXC; X-ray; 1.63 A; A=1038-1346.
DR   PDB; 4O3T; X-ray; 2.99 A; B=25-567.
DR   PDB; 4O3U; X-ray; 3.04 A; B=25-567.
DR   PDB; 4R1V; X-ray; 1.20 A; A=1055-1345.
DR   PDB; 4R1Y; X-ray; 2.00 A; A=1055-1346.
DR   PDB; 4XMO; X-ray; 1.75 A; A=1048-1350.
DR   PDB; 4XYF; X-ray; 1.85 A; A=1048-1351.
DR   PDB; 5DG5; X-ray; 2.60 A; A/B=1038-1346.
DR   PDB; 5EOB; X-ray; 1.75 A; A=1038-1346.
DR   PDB; 5EYC; X-ray; 1.80 A; A=1048-1351.
DR   PDB; 5EYD; X-ray; 1.85 A; A=1048-1351.
DR   PDB; 5HLW; X-ray; 1.97 A; A=1057-1355.
DR   PDB; 5HNI; X-ray; 1.71 A; X/Y=1049-1360.
DR   PDB; 5HO6; X-ray; 1.97 A; A=1049-1360.
DR   PDB; 5HOA; X-ray; 2.14 A; A=1049-1360.
DR   PDB; 5HOR; X-ray; 2.20 A; A=1049-1360.
DR   PDB; 5HTI; X-ray; 1.66 A; A=1038-1346.
DR   PDB; 5T3Q; X-ray; 2.00 A; A=1048-1350.
DR   PDBsum; 1FYR; -.
DR   PDBsum; 1R0P; -.
DR   PDBsum; 1R1W; -.
DR   PDBsum; 1SHY; -.
DR   PDBsum; 1SSL; -.
DR   PDBsum; 1UX3; -.
DR   PDBsum; 2G15; -.
DR   PDBsum; 2RFN; -.
DR   PDBsum; 2RFS; -.
DR   PDBsum; 2UZX; -.
DR   PDBsum; 2UZY; -.
DR   PDBsum; 2WD1; -.
DR   PDBsum; 2WGJ; -.
DR   PDBsum; 2WKM; -.
DR   PDBsum; 3A4P; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3C1X; -.
DR   PDBsum; 3CCN; -.
DR   PDBsum; 3CD8; -.
DR   PDBsum; 3CE3; -.
DR   PDBsum; 3CTH; -.
DR   PDBsum; 3CTJ; -.
DR   PDBsum; 3DKC; -.
DR   PDBsum; 3DKF; -.
DR   PDBsum; 3DKG; -.
DR   PDBsum; 3EFJ; -.
DR   PDBsum; 3EFK; -.
DR   PDBsum; 3F66; -.
DR   PDBsum; 3F82; -.
DR   PDBsum; 3I5N; -.
DR   PDBsum; 3L8V; -.
DR   PDBsum; 3LQ8; -.
DR   PDBsum; 3Q6U; -.
DR   PDBsum; 3Q6W; -.
DR   PDBsum; 3QTI; -.
DR   PDBsum; 3R7O; -.
DR   PDBsum; 3RHK; -.
DR   PDBsum; 3U6H; -.
DR   PDBsum; 3U6I; -.
DR   PDBsum; 3VW8; -.
DR   PDBsum; 3ZBX; -.
DR   PDBsum; 3ZC5; -.
DR   PDBsum; 3ZCL; -.
DR   PDBsum; 3ZXZ; -.
DR   PDBsum; 3ZZE; -.
DR   PDBsum; 4AOI; -.
DR   PDBsum; 4AP7; -.
DR   PDBsum; 4DEG; -.
DR   PDBsum; 4DEH; -.
DR   PDBsum; 4DEI; -.
DR   PDBsum; 4EEV; -.
DR   PDBsum; 4GG5; -.
DR   PDBsum; 4GG7; -.
DR   PDBsum; 4IWD; -.
DR   PDBsum; 4K3J; -.
DR   PDBsum; 4KNB; -.
DR   PDBsum; 4MXC; -.
DR   PDBsum; 4O3T; -.
DR   PDBsum; 4O3U; -.
DR   PDBsum; 4R1V; -.
DR   PDBsum; 4R1Y; -.
DR   PDBsum; 4XMO; -.
DR   PDBsum; 4XYF; -.
DR   PDBsum; 5DG5; -.
DR   PDBsum; 5EOB; -.
DR   PDBsum; 5EYC; -.
DR   PDBsum; 5EYD; -.
DR   PDBsum; 5HLW; -.
DR   PDBsum; 5HNI; -.
DR   PDBsum; 5HO6; -.
DR   PDBsum; 5HOA; -.
DR   PDBsum; 5HOR; -.
DR   PDBsum; 5HTI; -.
DR   PDBsum; 5T3Q; -.
DR   ProteinModelPortal; P08581; -.
DR   SMR; P08581; -.
DR   BioGrid; 110391; 39.
DR   DIP; DIP-6023N; -.
DR   IntAct; P08581; 87.
DR   MINT; MINT-4837114; -.
DR   STRING; 9606.ENSP00000317272; -.
DR   BindingDB; P08581; -.
DR   ChEMBL; CHEMBL3717; -.
DR   DrugBank; DB07969; 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol.
DR   DrugBank; DB08875; Cabozantinib.
DR   DrugBank; DB08865; Crizotinib.
DR   DrugBank; DB02152; K-252a.
DR   DrugBank; DB05216; MP470.
DR   DrugBank; DB06995; N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide.
DR   DrugBank; DB05153; XL184.
DR   GuidetoPHARMACOLOGY; 1815; -.
DR   iPTMnet; P08581; -.
DR   PhosphoSitePlus; P08581; -.
DR   SwissPalm; P08581; -.
DR   UniCarbKB; P08581; -.
DR   BioMuta; MET; -.
DR   DMDM; 251757497; -.
DR   OGP; P08581; -.
DR   EPD; P08581; -.
DR   MaxQB; P08581; -.
DR   PaxDb; P08581; -.
DR   PeptideAtlas; P08581; -.
DR   PRIDE; P08581; -.
DR   DNASU; 4233; -.
DR   Ensembl; ENST00000318493; ENSP00000317272; ENSG00000105976. [P08581-2]
DR   Ensembl; ENST00000397752; ENSP00000380860; ENSG00000105976. [P08581-1]
DR   Ensembl; ENST00000436117; ENSP00000410980; ENSG00000105976. [P08581-3]
DR   GeneID; 4233; -.
DR   KEGG; hsa:4233; -.
DR   UCSC; uc003vij.4; human. [P08581-1]
DR   CTD; 4233; -.
DR   DisGeNET; 4233; -.
DR   GeneCards; MET; -.
DR   HGNC; HGNC:7029; MET.
DR   HPA; CAB005282; -.
DR   HPA; CAB018577; -.
DR   HPA; HPA055607; -.
DR   MalaCards; MET; -.
DR   MIM; 114550; phenotype.
DR   MIM; 164860; gene.
DR   MIM; 605074; phenotype.
DR   MIM; 607278; phenotype.
DR   MIM; 616705; phenotype.
DR   neXtProt; NX_P08581; -.
DR   OpenTargets; ENSG00000105976; -.
DR   Orphanet; 106; Autism.
DR   Orphanet; 47044; Familial papillary renal cell carcinoma.
DR   PharmGKB; PA30763; -.
DR   eggNOG; KOG1095; Eukaryota.
DR   eggNOG; KOG3610; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00810000125384; -.
DR   HOGENOM; HOG000220900; -.
DR   HOVERGEN; HBG006348; -.
DR   InParanoid; P08581; -.
DR   KO; K05099; -.
DR   OMA; QRVDLFM; -.
DR   PhylomeDB; P08581; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-416550; Sema4D mediated inhibition of cell attachment and migration.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6806942; MET Receptor Activation.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8851805; MET activates RAS signaling.
DR   Reactome; R-HSA-8851907; MET activates PI3K/AKT signaling.
DR   Reactome; R-HSA-8865999; MET activates PTPN11.
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   Reactome; R-HSA-8875360; InlB-mediated entry of Listeria monocytogenes into host cell.
DR   Reactome; R-HSA-8875513; MET interacts with TNS proteins.
DR   Reactome; R-HSA-8875555; MET activates RAP1 and RAC1.
DR   Reactome; R-HSA-8875656; MET receptor recycling.
DR   Reactome; R-HSA-8875791; MET activates STAT3.
DR   SignaLink; P08581; -.
DR   SIGNOR; P08581; -.
DR   ChiTaRS; MET; human.
DR   EvolutionaryTrace; P08581; -.
DR   GeneWiki; C-Met; -.
DR   GenomeRNAi; 4233; -.
DR   PRO; PR:P08581; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000105976; -.
DR   CleanEx; HS_MET; -.
DR   ExpressionAtlas; P08581; baseline and differential.
DR   Genevisible; P08581; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:MGI.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005008; F:hepatocyte growth factor-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IMP:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0001886; P:endothelial cell morphogenesis; IDA:UniProtKB.
DR   GO; GO:0035635; P:entry of bacterium into host cell; TAS:Reactome.
DR   GO; GO:0061436; P:establishment of skin barrier; IMP:CAFA.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0010507; P:negative regulation of autophagy; NAS:ParkinsonsUK-UCL.
DR   GO; GO:1905098; P:negative regulation of guanyl-nucleotide exchange factor activity; IDA:CAFA.
DR   GO; GO:1901299; P:negative regulation of hydrogen peroxide-mediated programmed cell death; IMP:BHF-UCL.
DR   GO; GO:0035024; P:negative regulation of Rho protein signal transduction; IDA:CAFA.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; IDA:CAFA.
DR   GO; GO:0070495; P:negative regulation of thrombin-activated receptor signaling pathway; IDA:CAFA.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0050918; P:positive chemotaxis; IDA:UniProtKB.
DR   GO; GO:2001028; P:positive regulation of endothelial cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:CAFA.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002165; Plexin_repeat.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR016201; PSI.
DR   InterPro; IPR001627; Semap_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016244; Tyr_kinase_HGF/MSP_rcpt.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01437; PSI; 1.
DR   Pfam; PF01403; Sema; 1.
DR   Pfam; PF01833; TIG; 3.
DR   PIRSF; PIRSF000617; TyrPK_HGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00429; IPT; 4.
DR   SMART; SM00423; PSI; 1.
DR   SMART; SM00630; Sema; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF101912; SSF101912; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF81296; SSF81296; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS51004; SEMA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding;
KW   Chromosomal rearrangement; Complete proteome; Deafness;
KW   Disease mutation; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Non-syndromic deafness; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     24       {ECO:0000255}.
FT   CHAIN        25   1390       Hepatocyte growth factor receptor.
FT                                /FTId=PRO_0000024440.
FT   TOPO_DOM     25    932       Extracellular. {ECO:0000255}.
FT   TRANSMEM    933    955       Helical. {ECO:0000255}.
FT   TOPO_DOM    956   1390       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    515       Sema. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00352}.
FT   DOMAIN      563    655       IPT/TIG 1.
FT   DOMAIN      657    739       IPT/TIG 2.
FT   DOMAIN      742    836       IPT/TIG 3.
FT   DOMAIN     1078   1345       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    1084   1092       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION     1212   1390       Interaction with RANBP9.
FT   REGION     1320   1359       Interaction with MUC20.
FT                                {ECO:0000269|PubMed:15314156}.
FT   ACT_SITE   1204   1204       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING    1110   1110       ATP.
FT   SITE        307    308       Cleavage. {ECO:0000255}.
FT   SITE       1003   1003       Required for ligand-induced CBL-mediated
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:12244174}.
FT   SITE       1009   1010       Breakpoint for translocation to form TPR-
FT                                MET oncogene.
FT   MOD_RES     966    966       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     977    977       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     990    990       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     997    997       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1000   1000       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1003   1003       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1230   1230       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12475979}.
FT   MOD_RES    1234   1234       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12475979}.
FT   MOD_RES    1235   1235       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12475979,
FT                                ECO:0000269|PubMed:1655790}.
FT   MOD_RES    1289   1289       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1349   1349       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12475979,
FT                                ECO:0000269|PubMed:7513258}.
FT   MOD_RES    1356   1356       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15735664,
FT                                ECO:0000269|PubMed:7513258}.
FT   MOD_RES    1365   1365       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12475979}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    106    106       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19196183}.
FT   CARBOHYD    149    149       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    399    399       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    405    405       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    607    607       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    635    635       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    785    785       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    879    879       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    930    930       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     95    101
FT   DISULFID     98    160
FT   DISULFID    133    141
FT   DISULFID    172    175
FT   DISULFID    298    363
FT   DISULFID    385    397
FT   DISULFID    520    538
FT   DISULFID    526    561
FT   DISULFID    529    545
FT   DISULFID    541    551
FT   VAR_SEQ     755    764       SGGSTITGVG -> RHVNIALIQR (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_042447.
FT   VAR_SEQ     755    755       S -> STWWKEPLNIVSFLFCFAS (in isoform 2).
FT                                {ECO:0000303|PubMed:2819873}.
FT                                /FTId=VSP_005005.
FT   VAR_SEQ     765   1390       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_042448.
FT   VARIANT     143    143       R -> Q (in dbSNP:rs35469582).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041738.
FT   VARIANT     150    150       H -> Y (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_064855.
FT   VARIANT     156    156       S -> L (in dbSNP:rs56311081).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041739.
FT   VARIANT     168    168       E -> D (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation; dbSNP:rs55985569).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_041740.
FT   VARIANT     238    238       L -> S (in dbSNP:rs34349517).
FT                                /FTId=VAR_032478.
FT   VARIANT     316    316       I -> M (in dbSNP:rs35225896).
FT                                /FTId=VAR_032479.
FT   VARIANT     320    320       A -> V (in dbSNP:rs35776110).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006285.
FT   VARIANT     375    375       N -> S (in dbSNP:rs33917957).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032480.
FT   VARIANT     385    385       C -> Y (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation; dbSNP:rs752055485).
FT                                {ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_064856.
FT   VARIANT     773    773       P -> L (in gastric cancer;
FT                                dbSNP:rs771333219).
FT                                {ECO:0000269|PubMed:12920089}.
FT                                /FTId=VAR_032481.
FT   VARIANT     841    841       F -> V (in DFNB97; dbSNP:rs794728016).
FT                                {ECO:0000269|PubMed:25941349}.
FT                                /FTId=VAR_075757.
FT   VARIANT     964   1010       Missing (in OSFD; loss of CBL-mediated
FT                                destabilization).
FT                                {ECO:0000269|PubMed:26637977}.
FT                                /FTId=VAR_076584.
FT   VARIANT     970    970       R -> C (in dbSNP:rs34589476).
FT                                {ECO:0000269|PubMed:17053076,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_032482.
FT   VARIANT     991    991       P -> S (in gastric cancer; prolonged
FT                                tyrosine phosphorylation in response to
FT                                HGF/SF; transforming activity in athymic
FT                                nude mice; dbSNP:rs768678989).
FT                                {ECO:0000269|PubMed:11042681}.
FT                                /FTId=VAR_032483.
FT   VARIANT     992    992       T -> I (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation; dbSNP:rs56391007).
FT                                {ECO:0000269|PubMed:11042681,
FT                                ECO:0000269|PubMed:17053076,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_032484.
FT   VARIANT    1003   1003       Y -> S (probable disease-associated
FT                                mutation found in lesional sample from a
FT                                patient with sporadically occurring,
FT                                unilateral osteofibrous dysplasia;
FT                                somatic mutation; complete loss of
FT                                ligand-induced CBL-mediated
FT                                ubiquitination, resulting in protein
FT                                stabilization).
FT                                {ECO:0000269|PubMed:12244174}.
FT                                /FTId=VAR_076585.
FT   VARIANT    1092   1092       V -> I (in RCCP; constitutive
FT                                autophosphorylation; dbSNP:rs786202724).
FT                                {ECO:0000269|PubMed:10327054,
FT                                ECO:0000269|PubMed:10417759,
FT                                ECO:0000269|PubMed:10433944}.
FT                                /FTId=VAR_032485.
FT   VARIANT    1094   1094       H -> L (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054}.
FT                                /FTId=VAR_032486.
FT   VARIANT    1094   1094       H -> R (in RCCP; causes malignant
FT                                transformation in cell lines;
FT                                dbSNP:rs121913243).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9563489}.
FT                                /FTId=VAR_032487.
FT   VARIANT    1094   1094       H -> Y (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines;
FT                                dbSNP:rs121913244).
FT                                {ECO:0000269|PubMed:10327054}.
FT                                /FTId=VAR_032488.
FT   VARIANT    1106   1106       H -> D (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054,
FT                                ECO:0000269|PubMed:10433944}.
FT                                /FTId=VAR_032489.
FT   VARIANT    1131   1131       M -> T (in RCCP; germline mutation;
FT                                dbSNP:rs121913668).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006286.
FT   VARIANT    1173   1173       T -> I (in HCC; dbSNP:rs121913675).
FT                                {ECO:0000269|PubMed:9927037}.
FT                                /FTId=VAR_032490.
FT   VARIANT    1188   1188       V -> L (in RCCP; germline mutation;
FT                                dbSNP:rs121913669).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006287.
FT   VARIANT    1195   1195       L -> V (in RCCP; somatic mutation;
FT                                dbSNP:rs121913673).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006288.
FT   VARIANT    1220   1220       V -> I (in RCCP; germline mutation;
FT                                dbSNP:rs121913670).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006289.
FT   VARIANT    1228   1228       D -> H (in RCCP; somatic mutation).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006291.
FT   VARIANT    1228   1228       D -> N (in RCCP; germline mutation;
FT                                dbSNP:rs121913671).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006290.
FT   VARIANT    1230   1230       Y -> C (in RCCP; germline mutation;
FT                                dbSNP:rs121913246).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006292.
FT   VARIANT    1230   1230       Y -> D (in RCCP; constitutive
FT                                autophosphorylation; causes malignant
FT                                transformation in cell lines).
FT                                {ECO:0000269|PubMed:10327054,
FT                                ECO:0000269|PubMed:10433944}.
FT                                /FTId=VAR_032491.
FT   VARIANT    1230   1230       Y -> H (in RCCP; somatic mutation;
FT                                dbSNP:rs121913247).
FT                                {ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006293.
FT   VARIANT    1244   1244       K -> R (in HCC; dbSNP:rs121913677).
FT                                {ECO:0000269|PubMed:9927037}.
FT                                /FTId=VAR_032492.
FT   VARIANT    1250   1250       M -> I (in HCC; dbSNP:rs121913676).
FT                                {ECO:0000269|PubMed:9927037}.
FT                                /FTId=VAR_032493.
FT   VARIANT    1250   1250       M -> T (in RCCP; somatic mutation;
FT                                dbSNP:rs121913245).
FT                                {ECO:0000269|PubMed:10433944,
FT                                ECO:0000269|PubMed:9140397}.
FT                                /FTId=VAR_006294.
FT   VARIANT    1294   1294       V -> I (found in a case of cancer of
FT                                unknown primary origin; the mutated
FT                                receptor is still functional and can
FT                                sustain the transformed phenotype;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:20949619}.
FT                                /FTId=VAR_064857.
FT   MUTAGEN    1234   1234       Y->F: Complete loss of kinase activity
FT                                and of ligand-induced ubiquitination.
FT                                Alters interaction with PTPN1 and PTPN2.
FT                                Loss of interaction with PTPN1 and PTPN2;
FT                                when associated with F-1235.
FT                                {ECO:0000269|PubMed:12244174,
FT                                ECO:0000269|PubMed:18819921}.
FT   MUTAGEN    1235   1235       Y->F: Complete loss of kinase activity.
FT                                Alters interaction with PTPN1 and PTPN2.
FT                                Loss of interaction with PTPN1 and PTPN2;
FT                                when associated with F-1234.
FT                                {ECO:0000269|PubMed:12244174,
FT                                ECO:0000269|PubMed:18819921}.
FT   MUTAGEN    1313   1313       Y->F: No effect on ligand-induced CBL-
FT                                mediated ubiquitination; when associated
FT                                with F-1349, F-1356 and F-1365.
FT                                {ECO:0000269|PubMed:12244174}.
FT   MUTAGEN    1349   1349       Y->F: No effect on ligand-induced CBL-
FT                                mediated ubiquitination; when associated
FT                                with F-1313, F-1356 and F-1365.
FT                                {ECO:0000269|PubMed:12244174}.
FT   MUTAGEN    1356   1356       Y->F: No effect on ligand-induced CBL-
FT                                mediated ubiquitination; when associated
FT                                with F-1313, F-1349 and F-1365.
FT                                {ECO:0000269|PubMed:12244174}.
FT   MUTAGEN    1365   1365       Y->F: No effect on ligand-induced CBL-
FT                                mediated ubiquitination; when associated
FT                                with F-1313, F-1349 and F-1356.
FT                                {ECO:0000269|PubMed:12244174}.
FT   CONFLICT    237    237       V -> A (in Ref. 3; ACF47606).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       K -> R (in Ref. 3; ACF47606).
FT                                {ECO:0000305}.
FT   CONFLICT    720    720       F -> S (in Ref. 3; ACF47606).
FT                                {ECO:0000305}.
FT   CONFLICT   1191   1191       G -> A (in Ref. 1; AAA59591).
FT                                {ECO:0000305}.
FT   CONFLICT   1272   1272       L -> V (in Ref. 1; AAA59591, 2; CAB56793
FT                                and 6; AAA59590). {ECO:0000305}.
FT   STRAND       45     47       {ECO:0000244|PDB:2UZX}.
FT   STRAND       52     58       {ECO:0000244|PDB:2UZX}.
FT   STRAND       61     66       {ECO:0000244|PDB:2UZX}.
FT   STRAND       69     74       {ECO:0000244|PDB:2UZX}.
FT   TURN         75     77       {ECO:0000244|PDB:2UZX}.
FT   STRAND       80     84       {ECO:0000244|PDB:2UZX}.
FT   STRAND       89     91       {ECO:0000244|PDB:4K3J}.
FT   STRAND       93     95       {ECO:0000244|PDB:4K3J}.
FT   STRAND       97     99       {ECO:0000244|PDB:1SHY}.
FT   HELIX       103    105       {ECO:0000244|PDB:4O3T}.
FT   STRAND      111    113       {ECO:0000244|PDB:4K3J}.
FT   STRAND      119    123       {ECO:0000244|PDB:2UZX}.
FT   STRAND      125    133       {ECO:0000244|PDB:2UZX}.
FT   STRAND      135    139       {ECO:0000244|PDB:2UZX}.
FT   STRAND      141    145       {ECO:0000244|PDB:2UZX}.
FT   STRAND      155    160       {ECO:0000244|PDB:4K3J}.
FT   STRAND      182    189       {ECO:0000244|PDB:2UZX}.
FT   STRAND      192    199       {ECO:0000244|PDB:2UZX}.
FT   STRAND      213    219       {ECO:0000244|PDB:2UZX}.
FT   HELIX       231    233       {ECO:0000244|PDB:2UZX}.
FT   HELIX       239    241       {ECO:0000244|PDB:2UZX}.
FT   TURN        242    244       {ECO:0000244|PDB:2UZX}.
FT   STRAND      247    255       {ECO:0000244|PDB:2UZX}.
FT   STRAND      258    268       {ECO:0000244|PDB:2UZX}.
FT   STRAND      272    274       {ECO:0000244|PDB:2UZX}.
FT   STRAND      277    281       {ECO:0000244|PDB:2UZX}.
FT   STRAND      284    286       {ECO:0000244|PDB:2UZX}.
FT   STRAND      292    300       {ECO:0000244|PDB:2UZX}.
FT   STRAND      312    314       {ECO:0000244|PDB:2UZX}.
FT   STRAND      316    323       {ECO:0000244|PDB:2UZX}.
FT   HELIX       327    333       {ECO:0000244|PDB:2UZX}.
FT   STRAND      341    349       {ECO:0000244|PDB:2UZX}.
FT   STRAND      356    366       {ECO:0000244|PDB:2UZX}.
FT   HELIX       367    374       {ECO:0000244|PDB:2UZX}.
FT   HELIX       380    382       {ECO:0000244|PDB:4K3J}.
FT   STRAND      383    385       {ECO:0000244|PDB:4K3J}.
FT   HELIX       387    390       {ECO:0000244|PDB:2UZX}.
FT   STRAND      392    394       {ECO:0000244|PDB:1SHY}.
FT   TURN        395    397       {ECO:0000244|PDB:4O3T}.
FT   STRAND      418    422       {ECO:0000244|PDB:2UZX}.
FT   STRAND      424    427       {ECO:0000244|PDB:2UZX}.
FT   TURN        429    436       {ECO:0000244|PDB:2UZX}.
FT   STRAND      439    447       {ECO:0000244|PDB:2UZX}.
FT   STRAND      450    457       {ECO:0000244|PDB:2UZX}.
FT   STRAND      462    466       {ECO:0000244|PDB:2UZX}.
FT   STRAND      469    471       {ECO:0000244|PDB:4K3J}.
FT   STRAND      476    480       {ECO:0000244|PDB:4K3J}.
FT   STRAND      490    493       {ECO:0000244|PDB:2UZX}.
FT   TURN        496    498       {ECO:0000244|PDB:4O3T}.
FT   STRAND      501    506       {ECO:0000244|PDB:2UZX}.
FT   STRAND      509    514       {ECO:0000244|PDB:2UZX}.
FT   HELIX       518    521       {ECO:0000244|PDB:4K3J}.
FT   HELIX       526    531       {ECO:0000244|PDB:2UZX}.
FT   HELIX       534    536       {ECO:0000244|PDB:2UZX}.
FT   STRAND      538    540       {ECO:0000244|PDB:2UZX}.
FT   STRAND      545    548       {ECO:0000244|PDB:2UZX}.
FT   STRAND      552    554       {ECO:0000244|PDB:2UZX}.
FT   STRAND      557    559       {ECO:0000244|PDB:2UZX}.
FT   STRAND      564    572       {ECO:0000244|PDB:2UZX}.
FT   STRAND      580    586       {ECO:0000244|PDB:2UZX}.
FT   STRAND      590    592       {ECO:0000244|PDB:2UZX}.
FT   STRAND      595    598       {ECO:0000244|PDB:2UZX}.
FT   STRAND      602    605       {ECO:0000244|PDB:2UZX}.
FT   HELIX       614    616       {ECO:0000244|PDB:2UZX}.
FT   STRAND      619    625       {ECO:0000244|PDB:2UZX}.
FT   STRAND      637    641       {ECO:0000244|PDB:2UZX}.
FT   STRAND      646    650       {ECO:0000244|PDB:2UZX}.
FT   HELIX      1048   1050       {ECO:0000244|PDB:4EEV}.
FT   HELIX      1055   1057       {ECO:0000244|PDB:3F66}.
FT   HELIX      1060   1066       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1067   1069       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1073   1075       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1076   1087       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1090   1098       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1100   1102       {ECO:0000244|PDB:4EEV}.
FT   STRAND     1104   1111       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1118   1132       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1144   1146       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1149   1151       {ECO:0000244|PDB:3F66}.
FT   STRAND     1154   1158       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1165   1170       {ECO:0000244|PDB:4R1V}.
FT   TURN       1172   1174       {ECO:0000244|PDB:3ZCL}.
FT   HELIX      1178   1197       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1207   1209       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1210   1212       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1218   1220       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1224   1226       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1232   1234       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1236   1238       {ECO:0000244|PDB:4KNB}.
FT   TURN       1239   1241       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1243   1245       {ECO:0000244|PDB:4KNB}.
FT   HELIX      1247   1249       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1252   1257       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1262   1277       {ECO:0000244|PDB:4R1V}.
FT   STRAND     1283   1287       {ECO:0000244|PDB:4EEV}.
FT   HELIX      1289   1291       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1292   1297       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1310   1319       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1324   1326       {ECO:0000244|PDB:4R1V}.
FT   HELIX      1330   1342       {ECO:0000244|PDB:4R1V}.
FT   TURN       1354   1358       {ECO:0000244|PDB:1R0P}.
SQ   SEQUENCE   1390 AA;  155541 MW;  9CF896D1273905C3 CRC64;
     MKAPAVLAPG ILVLLFTLVQ RSNGECKEAL AKSEMNVNMK YQLPNFTAET PIQNVILHEH
     HIFLGATNYI YVLNEEDLQK VAEYKTGPVL EHPDCFPCQD CSSKANLSGG VWKDNINMAL
     VVDTYYDDQL ISCGSVNRGT CQRHVFPHNH TADIQSEVHC IFSPQIEEPS QCPDCVVSAL
     GAKVLSSVKD RFINFFVGNT INSSYFPDHP LHSISVRRLK ETKDGFMFLT DQSYIDVLPE
     FRDSYPIKYV HAFESNNFIY FLTVQRETLD AQTFHTRIIR FCSINSGLHS YMEMPLECIL
     TEKRKKRSTK KEVFNILQAA YVSKPGAQLA RQIGASLNDD ILFGVFAQSK PDSAEPMDRS
     AMCAFPIKYV NDFFNKIVNK NNVRCLQHFY GPNHEHCFNR TLLRNSSGCE ARRDEYRTEF
     TTALQRVDLF MGQFSEVLLT SISTFIKGDL TIANLGTSEG RFMQVVVSRS GPSTPHVNFL
     LDSHPVSPEV IVEHTLNQNG YTLVITGKKI TKIPLNGLGC RHFQSCSQCL SAPPFVQCGW
     CHDKCVRSEE CLSGTWTQQI CLPAIYKVFP NSAPLEGGTR LTICGWDFGF RRNNKFDLKK
     TRVLLGNESC TLTLSESTMN TLKCTVGPAM NKHFNMSIII SNGHGTTQYS TFSYVDPVIT
     SISPKYGPMA GGTLLTLTGN YLNSGNSRHI SIGGKTCTLK SVSNSILECY TPAQTISTEF
     AVKLKIDLAN RETSIFSYRE DPIVYEIHPT KSFISGGSTI TGVGKNLNSV SVPRMVINVH
     EAGRNFTVAC QHRSNSEIIC CTTPSLQQLN LQLPLKTKAF FMLDGILSKY FDLIYVHNPV
     FKPFEKPVMI SMGNENVLEI KGNDIDPEAV KGEVLKVGNK SCENIHLHSE AVLCTVPNDL
     LKLNSELNIE WKQAISSTVL GKVIVQPDQN FTGLIAGVVS ISTALLLLLG FFLWLKKRKQ
     IKDLGSELVR YDARVHTPHL DRLVSARSVS PTTEMVSNES VDYRATFPED QFPNSSQNGS
     CRQVQYPLTD MSPILTSGDS DISSPLLQNT VHIDLSALNP ELVQAVQHVV IGPSSLIVHF
     NEVIGRGHFG CVYHGTLLDN DGKKIHCAVK SLNRITDIGE VSQFLTEGII MKDFSHPNVL
     SLLGICLRSE GSPLVVLPYM KHGDLRNFIR NETHNPTVKD LIGFGLQVAK GMKYLASKKF
     VHRDLAARNC MLDEKFTVKV ADFGLARDMY DKEYYSVHNK TGAKLPVKWM ALESLQTQKF
     TTKSDVWSFG VLLWELMTRG APPYPDVNTF DITVYLLQGR RLLQPEYCPD PLYEVMLKCW
     HPKAEMRPSF SELVSRISAI FSTFIGEHYV HVNATYVNVK CVAPYPSLLS SEDNADDEVD
     TRPASFWETS
//
